Offering new hope for a rare form of non-hodgkin's lymphoma: a discussion with dr. ellen kim on hybryte(tm) from soligenix

New york, new york--(newsfile corp. - july 6, 2021) - pcg digital -- a rare form of non-hodgkin's lymphoma, cutaneous t-cell lymphoma (ctcl) has no current fda-approved first-line therapies. there are roughly 3,000 new ctcl cases in the united states each year, with more than 20,000 patients living with ctcl.small cap biotech soligenix (nasdaq:sngx) is developing and moving toward potential commercialization of hybryte™ (sgx301 or synthetic hypericin) as a novel first in class photodynamic therapy...
SNGX Ratings Summary
SNGX Quant Ranking